A Phase 1, Randomised, Open-label, 4-Period Crossover Study to Develop an In Vitro-In Vivo Correlation for Olaparib Tablets in Subjects With Solid Tumors
Status: Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 09 Dec 2019
Price : $35 *
At a glance
- Drugs Olaparib (Primary)
- Indications Solid tumours
- Focus Pharmacokinetics
- Acronyms IVIVC
- Sponsors AstraZeneca
- 04 Dec 2019 Planned End Date changed from 31 Dec 2019 to 31 Mar 2020.
- 29 May 2019 Planned End Date changed from 17 Jun 2019 to 31 Dec 2019.
- 29 May 2019 Status changed from recruiting to active, no longer recruiting.